EDAP TMS SA demonstrated notable revenue growth in FY2025, driven by its core High Intensity Focused Ultrasound (HIFU) business and expanding adoption of the Focal One system, particularly in the U.S. market. The FDA's recent 510(k) clearance enhances the system with advanced imaging and workflow improvements, reinforcing EDAP’s competitive position. Despite topline growth and gross margin expansion, the company operated at a loss amid sustained R&D and SG&A investments. Cash reserves support ongoing innovation but reflect constrained free cash flow. Future growth hinges on clinical trial progress, expanded indications, and reimbursement dynamics.